AXSM
Axsome Therapeutics Powers Ahead in Q2 2026: Strong Commercial Growth and Regulatory Progress
August 10, 2026 – Axsome Therapeutics made significant strides in the second quarter of this year, marked by robust commercial growth and important regulatory and clinical progress across its innovative neuroscience pipeline. The company's commercial portfolio generated $218 million in net product revenue during the quarter, a staggering 46%